Vaccibody AS was established 2007 as a spin-off from the University of Oslo and Oslo University hospital. The Vaccibody technology was conceived in the laboratory of Professor Bjarne Bogen, one of Europe’s leading immunologists. With Professor Inger Sandlie and Agnete Fredriksen he invented the basic construct of a novel vaccine molecule, and impressive preclinical results in animal studies was demonstrated. All rights to the technology was assigned to Vaccibody at the company establishment.
With funding from The Norwegian Research Council , Innovation Norway, and private investors, the company has established the proof of concept for the vaccine platform. Vaccibody has now started the development of an immuntherapy against HPV-induced malignancies, such as precanceous lesions of cervical cancer.
Funding Rounds (2) - $3.49MUpdate
Current Team (3)Update
|Jun 18, 2015||PRWeb Sitemap - Cervical Dysplasia Therapeutic Products and Pipeline Assessment Review H1 2015 Market Research Report Available at RnRMarketResearch.com|
|Jun 26, 2013||Business Wire - Vaccibody raises 2547000 in grant round|
|Jun 26, 2013||vaccibody.com - Vaccibody raises 943077 in seed round|
Oslo Research Park